Role of oral anticoagulation in management of atrial fibrillation

Heart

Volumn 90, Issue 7, 2004, Pages 813-817

  Crystal, Eugene ^a,b   Connolly, Stuart J ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALLOPURINOL; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; CARDIAC AGENT; DISULFIRAM; LEVOTHYROXINE; PLACEBO; TESTOSTERONE; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; MORTALITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TREATMENT INDICATION;

EID: 3042552139     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.021642     Document Type: Review

References (19)

1. American Heart Organization. 2001 Heart and stroke statistical update. Dallas, Texas: American Heart Association, 2001:18.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
3. Flegel KM, Shipley WJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987;i:526-9.
4. Hort RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32:803-8. ▶ Comprehensive editorial review of the concepts behind the use of oral anticoagulants, with in-depth discussions of associated controversies.
5. SPAF Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527-39.
6. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94.
7. Von Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
8. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33. ▶ Largest of existing trials on the rhythm versus rate control. The study showed no survival benefit of rhythm control strategy by pharmacological means over rate control approach.
9. Carlsson J. STAF - a randomized trial of strategies in atrial fibrillation. J Am Coll Card 2001;38:603A.
10. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;i:175-9.
11. BAATAF Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston area anticoagulation trial for atrial fibrillation investigators. N Engl J Med 1990;323:1505-11.
12. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
13. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med 1992;327:1406-12.
14. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European atrial fibrillation trial) study group. Lancet 1993;342:1255-62.
15. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
16. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50. ▶ The most recent comprehensive guidelines on the management of the atrial fibrillation, including use of oral anticoagulants.
17. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. ▶ Individual patient data meta-analysis comparing oral anticoagulation and antiplatelet regimens demonstrated significant superiority of oral anticoagulation in end points of stroke and all cardiovascular events.
18. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;147:1361-4.
19. Hort RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The stroke prevention in atrial fibrillation (SPAF) investigators. Stroke 1999;30:1223-9.